CTIS2024-515836-61-00进行中（未招募）1 期
Combination of ALpelisib and Trametinib in progressive REfractory Meningiomas
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Phase I/II study with lapatinib plus trametinib in patients with metastatic KRAS mutant non-small cell lung cancer10038666non-small cell lung cancerNL-OMON46994Antoni van Leeuwenhoek Ziekenhuis132
进行中（未招募）
1 期
Phase I/II study with lapatinib plus trametinib in patients with metastaticnon-small cell lung cancer with a mutation in the KRAS genenon-small cell lung cancerEUCTR2014-002209-39-NLThe Netherlands Cancer Institute132
招募中
1 期
Imatinib and Pembrolizumab combination therapy for advanced KIT-mutant melanoma: a phase I/II trial (IMPAKT trial)Advanced KIT-mutant melanomaOther disease of skin or skin tissueJPRN-jRCTs031190202Funakoshi Takeru22
撤回
1 期
Study of Trametinib and Nab-paclitaxel in Patients With MelanomaMelanomaNCT02300935SCRI Development Innovations, LLC
已完成
2 期
First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GCAdvanced Gastric AdenocarcinomaNCT06238752Renmin Hospital of Wuhan University33